Related Experiment Videos
Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic
Insights
Captopril, an angiotensin converting enzyme inhibitor, improved renal plasma flow and reduced blood pressure in patients with diabetic nephropathy. This treatment protected kidney function by improving renal hemodynamics.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Diabetic nephropathy is a leading cause of chronic kidney disease.
- Hypertension exacerbates kidney damage in diabetic nephropathy.
- Angiotensin converting enzyme (ACE) inhibitors are used to manage hypertension and protect kidney function.
Purpose of the Study:
- To investigate the effects of ACE inhibition with captopril on renal hemodynamics and function in patients with diabetic nephropathy and hypertension.
- To assess the long-term impact of captopril on blood pressure and glomerular filtration rate (GFR) decline.
Main Methods:
- Patients with diabetic nephropathy and hypertension received captopril treatment.
- Renal plasma flow (RPF), filtration fraction (FF), and GFR were measured before and after treatment.
- Mean arterial blood pressure (MAP) and GFR deterioration rates were monitored over two years.
Main Results:
- Short-term (9 days) captopril treatment increased RPF and decreased FF without changing GFR.
- Long-term (2 years) captopril treatment significantly reduced MAP and slowed the rate of GFR deterioration.
- No correlation was found between blood pressure reduction and the improvement in GFR decline rate.
Conclusions:
- ACE inhibition with captopril improves renal hemodynamics in patients with diabetic nephropathy.
- Captopril effectively lowers blood pressure and protects renal function in this patient population.
- ACE inhibitors should be considered for blood pressure management in patients with diabetic nephropathy.
Abstract:
The effects of angiotensin converting enzyme inhibition with captopril were investigated in patients with diabetic nephropathy and hypertension. After nine days' treatment with captopril glomerular filtration rate was unchanged in 13 patients, whereas renal plasma flow had increased from 265 to 302 ml/min/1.73 m2 body surface area (p less than 0.05) and the filtration fraction had decreased from 14.3 to 12.8% (p less than 0.025). During two years' treatment with captopril in 14 patients the mean arterial blood pressure had fallen by 5 mm Hg (p less than 0.005) and the deterioration in glomerular filtration rate had decreased from 10.3 to 2.4 ml/min/year (p less than 0.005). There was no correlation between the fall in blood pressure and the reduction in the deterioration of glomerular filtration rate. These findings suggest that the effects of angiotensin converting enzyme inhibition on renal haemodynamics protect renal function. Inhibitors of angiotensin converting enzyme should be considered for lowering blood pressure in patients with diabetic nephropathy.